NASDAQ: RNTX
Rein Therapeutics Inc Stock Ownership - Who owns Rein Therapeutics?

Insider buying vs selling

Have Rein Therapeutics Inc insiders been buying or selling?

Buy
Sell
NameRoleDateSharesPriceValue
James Brian WindsorPresident and CEO2024-12-05239$2.24
$535.36Buy
James Brian WindsorPresident and CEO2024-12-05161$2.25
$362.25Buy

1 of 1

RNTX insiders have bought more... subscribe to Premium to read more.
Net Insider Buy/Sell (L12M) Ownership

Be the first to know when RNTX insiders and whales buy or sell their stock.

RNTX Shareholders

What type of owners hold Rein Therapeutics Inc stock?

Institutional
Insider
Retail
NameHoldSharesValueType
Muneer A. Satter71.27%16,609,449$20.26MInsider
Reinhard J. Ambros10.94%2,549,982$3.11MInsider
Novartis Bioventures Ltd8.92%2,079,394$2.54MInsider
Of Texastexas Am Investment Managment Co University7.77%1,810,457$2.21MInsider
University Of Texastexas Am Investment Management Co7.49%1,746,549$2.13MInsider
Bios Capital Management LP7.25%1,690,751$2.06MInstitution
Voss Capital LP6.15%1,433,686$1.75MInstitution
Brian M. Gallagher Jr.6.14%1,431,519$1.75MInsider
Armen Shanafelt4.70%1,094,987$1.34MInsider
LV Management Group LLC4.70%1,094,987$1.34MInsider

1 of 3

RNTX vs Biotech Stocks

TickerInst. %Insider %Net Insider (L12M)Net Insider (L3M)
RNTX16.03%83.97%Net Buying
CVKD3.34%54.56%Net SellingNet Selling
NXTC42.37%57.63%
LNAI11.06%88.94%
NRSN1.83%0.00%

Rein Therapeutics Stock Ownership FAQ

Who owns Rein Therapeutics?

Rein Therapeutics (NASDAQ: RNTX) is owned by 28.57% institutional shareholders, 149.61% Rein Therapeutics insiders, and 0.00% retail investors. Muneer A. Satter is the largest individual Rein Therapeutics shareholder, owning 16.61M shares representing 71.27% of the company. Muneer A. Satter's Rein Therapeutics shares are currently valued at $20.26M.

If you're new to stock investing, here's how to buy Rein Therapeutics stock.
WallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.

Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.